- February 17, 2017 HEALTH CANADA APPROVES OTSUKA AND LUNDBECK'S REXULTI TM (brexpiprazole) AS A TREATMENT FOR SCHIZOPHRENIA IN ADULTS
LUNDBECK CANADA’S CONTRIBUTION TO UNIVERSITE LAVAL’S FACULTY OF PHARMACY AND CREATION OF A MASTER OF ADVANCED STUDIES IN PSYCHIATRY October 5, 2014 IN PARTNERSHIP WITH THE IUSMQ -
October 28, 2014 LUNDBECK ANNOUNCES HEALTH CANADA APPROVAL OF TRINTELLIX™ (vortioxetine hydrobromide) FRO THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER -
- May 5, 2014 NEW ONCE-MONTHLY TREATMENT FOR SCHIZOPHRENIA, ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension), NOW AVAILABLE IN CANADA
- November 13, 2013 LUNDBECK CANADA LAUNCHES A NEW TREATMENT FOR A RARE FORM OF ACUTE LEUKEMIA
LUNDBECK CANADA OFFERS NEW TREATMENT OPTION FOR RELAPSED INDOLENT B-CELL NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
- September 13, 2012
LUNDBECK CANADA HAILS NEW NATIONAL STANDARD ON PSYCHOLOGICAL HEALTH AND SAFETY IN THE WORKPLACE
- January 16, 2013
Members of the media seeking further information may contact:
Corporate Communications Specialist, Public Affairs
For Customer Service inquiries, please contact:
CNS Representative, Customer Service
You are now leaving the Lundbeck Canada website. The Lundbeck Worldwide internet site that you have requested is intended for the residents of other countries as indicated on that site. This means that the site may contain information on pharmaceutical products or uses of those products that are not approved in Canada.
Do you wish to continue?